XIAMEN SINOPEG BIOTECH CO., LTD.

Xiamen Sinopeg Biotech Co., Ltd. is dedicated to drug delivery systems and related medical device business, focusing on the research, development, production and sales of high-end drug delivery carriers/auxiliary materials/APIs, medical materials, including but not limited to polyethylene glycol derivatives, lipid products, blood sugar control drug modifiers, block copolymers, ADC/ProTAC linkers, biodegradable polymers, exosomes, viral-like particles, as well as providing CDMO and solution services. These products are widely used in long-acting protein/peptide drugs, COVID-19 mRNA vaccines, small nucleic acid drugs, blood sugar control drugs, macromolecular micelle drugs, liposome drugs, gene therapy drugs, immunosuppressants, ADC drugs, ProTAC drugs, medical hydrogels, and other fields, placing the company in a leading position in the industry. SINOPEG holds 31 IP, 25 pending IP, and 16 DMFs that meet FDA requirements. The company has ISO13485 certification. The laboratory and production workshop are designed and built in accordance with the cGMP standard of FDA. We follow the requirements of ICH-Q7A to organize production at scale, to provide high quality polyethylene glycol derivatives products and services to customers globally.